C. difficile Workshop with Kevin Killeen
Please join us at World Vaccine Congress 2020, in Washington D.C.
April 6, 2020 at 10:00
WORKSHOP D (MORNING ONLY): TACKLE C. difficile
The Centers for Disease Control (CDC) has named C. difficile infections an urgent public health threat and the leading hospital-acquired infection in the U.S. With an enormous human toll, and significant health care costs, there is a clear need to prevent and treat this infection. Join us in this workshop as we hear from experts on their promising approaches to tackle the infection.
Workshop Leader: Kevin Killeen, Chief Scientific Officer, Matrivax
-Vaccine Effort Therapies
-Antibiotics: Merck’s DIFICID® (fidaxomicin)
-Fecal Microbiota Transplant
Kevin Killeen, Chief Scientific Officer, Matrivax R & D Corp
Mena Boules, Associate Medical Director, Medical Affairs, Gastroenterology, FERRING Pharmaceuticals
Pamela Sears, Vice President Clinical Science, Merck
Elizabeth Hohmann, Infectious Disease, Massachusetts General Hospital